

Amendments to the Claims

Please amend Claims 1, 4, 5 and 11.

Please cancel Claims 3 and 16.

The Claim Listing below will replace all prior versions of the claims in the application:

Claim Listing

1. (Currently Amended) A method of treating TNF α -mediated cachexia associated with cancer in a human comprising administering to the human an effective TNF α -inhibiting amount of an anti-TNF α chimeric antibody or antigen-binding fragment thereof, said antibody comprising a human constant region, wherein said anti-TNF α chimeric antibody or antigen-binding fragment thereof (i) competitively inhibits binding of A2 (ATCC Accession No. PTA-7045) to human TNF α to anti-TNF α chimeric monoclonal antibody eA2 and (ii) binds to a neutralizing epitope of human TNF α *in vivo* with an affinity of at least 1×10^8 liter/mole, measured as an association constant (Ka), as determined by Scatchard analysis.
2. (Previously Presented) A method of treating TNF α -mediated cachexia associated with cancer in a human comprising administering to the human an effective TNF α -inhibiting amount of an anti-TNF α chimeric antibody, wherein said anti-TNF α chimeric antibody binds to at least one epitope included in amino acids between 87-108 or both 59-80 and 87-108 of SEQ ID NO.:1 of hTNF, as determined by Geysen epitope mapping comprising use of TNF decapeptide pins which overlap at every second amino acid and synthesized on polyethylene pins.
3. (Canceled).
4. (Currently Amended) A method of treating TNF α -mediated cachexia associated with cancer in a human comprising administering to the human at least one anti-TNF α

~~chimeric monoclonal antibody eA2, or a TNF α binding or antigen-binding fragment thereof, said antibody comprising a human constant region, wherein said anti-TNF α antibody or antigen-binding fragment thereof (i) competitively inhibits binding of A2 (ATCC Accession No. PTA-7045) to human TNF α and (ii) binds to a neutralizing epitope of human TNF α *in vivo* with an affinity of at least 1×10^8 liter/mole, measured as an association constant (Ka), as determined by Scatchard analysis.~~

5. (Currently Amended) A method of treating TNF α -mediated cachexia associated with cancer in a human comprising administering to the human an effective TNF α -inhibiting amount of an anti-TNF α ~~chimeric~~ antibody or antigen-binding fragment thereof, wherein said anti-TNF α ~~chimeric~~ antibody comprises an IgG1 human constant region, and wherein said anti-TNF α antibody or antigen-binding fragment thereof (i) competitively inhibits binding of A2 (ATCC Accession No. PTA-7045) to human TNF α to anti-TNF α chimeric monoclonal antibody eA2 and (ii) binds to a neutralizing epitope of human TNF α *in vivo* with an affinity of at least 1×10^8 liter/mole, measured as an association constant (Ka), as determined by Scatchard analysis.
6. (Previously Presented) A method of treating TNF α -mediated cachexia associated with cancer in a human comprising administering to the human an effective TNF α -inhibiting amount of an anti-TNF α chimeric antibody, wherein said anti-TNF α chimeric antibody comprises an IgG1 constant region and binds to at least one epitope included in amino acids between 87-108 or both 59-80 and 87-108 of SEQ ID NO.:1 of hTNF, as determined by Geysen epitope mapping comprising use of TNF decapeptide pins which overlap at every second amino acid and synthesized on polyethylene pins.
7. (Previously Presented) A method of treating TNF α -mediated cachexia associated with cancer in a human comprising administering to the human an effective TNF α -inhibiting amount of an anti-TNF α chimeric antibody, wherein said anti-TNF α chimeric antibody comprises a non-human variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NO.:3 and SEQ ID NO.:5.

8. (Previously Presented) A method of treating TNF α -mediated cachexia associated with cancer in a human comprising administering to the human an effective TNF α -inhibiting amount of an anti-TNF α chimeric antibody, wherein said anti-TNF α chimeric antibody comprises an IgG1 human constant region and a non-human variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NO.:3 and SEQ ID NO.:5.
9. (Original) The method of Claim 7 wherein the non-human variable region comprises a polypeptide encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NO.:2 and SEQ ID NO.:4.
10. (Original) The method of Claim 8 wherein the non-human variable region comprises a polypeptide encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NO.:2 and SEQ ID NO.:4.
11. (Currently Amended) A method of treating TNF α -mediated cachexia associated with cancer in a human comprising administering to the human an effective TNF α -inhibiting amount of an anti-TNF α chimeric antibody or antigen-binding fragment thereof, said anti-TNF α antibody comprising a human constant region, wherein said anti-TNF α chimeric antibody or antigen-binding fragment thereof (i) has epitopic specificity identical to monoclonal antibody cA2 A2 (ATCC Accession No. PTA-7045) and (ii) binds to a neutralizing epitope of human TNF α *in vivo* with an affinity of at least 1×10^8 liter/mole, measured as an association constant (Ka), as determined by Scatchard analysis.

Claims 12.-13. (Canceled)

14. (Previously Presented) The method of Claim 1, wherein said anti-TNF α chimeric antibody is administered to the human by means of parenteral administration.

15. (Previously Presented) The method of Claim 1, wherein said anti-TNF α chimeric antibody is administered to the human by means of intravenous administration, subcutaneous administration or intramuscular administration.
16. (Canceled).
17. (Previously Presented) The method of Claim 1, wherein said anti-TNF α chimeric antibody is administered to the human orally.
18. (Previously Presented) The method of Claim 1, wherein said TNF α -inhibiting amount of the anti-TNF α chimeric antibody comprises a single or divided dose of about 0.1 - 50 mg/kg.
19. (Previously Presented) The method of Claim 18, wherein said single or divided dose is selected from the group consisting of: about a 0.1 - 1 mg/kg dose, about a 1.0 - 5 mg/kg dose, about a 5 - 10 mg/kg dose and about a 10 - 20 mg/kg dose.
20. (Previously Presented) The method of Claim 1, further comprising administering to the human an effective amount of a therapeutic agent selected from the group consisting of: radiotherapeutics, cytotoxic drugs, monoclonal antibodies, chimeric antibodies, antibody fragments, antibody regions, lymphokines, cytokines, hemopoietic growth factors and immunoglobulins.